10-Q: Verastem Oncology Reports Third Quarter 2024 Results and Highlights NDA Submission

Verastem Oncology completed its rolling NDA submission for the avutometinib and defactinib combination in recurrent KRAS mutant low-grade serous ovarian cancer and is seeking accelerated approval.

Summary

• Verastem Oncology reported a net loss of $24.0 million for the third quarter of 2024, compared to a net loss of $20.0 million for the same period in 2023.
• The company's cash, cash equivalents, and short-term investments totaled $113.2 million as of September 30, 2024.
• Operating expenses for the quarter were $37.0 million, up from $21.3 million in the third quarter of 2023, with research and development expenses increasing to $24.8 million from $13.9 million.
• The company completed its rolling New Drug Application (NDA) submission for the combination of avutometinib and defactinib for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC) in October 2024.
• Verastem is seeking accelerated approval and priority review from the FDA, with a potential approval decision by mid-2025.
• The company is also preparing for a potential U.S. commercial launch in mid-2025.
• Updated data from the RAMP 201 trial showed a confirmed overall response rate (ORR) of 31% in all evaluable patients, 44% in KRAS mutant LGSOC, and 17% in KRAS wild-type LGSOC.
• The RAMP 301 Phase 3 trial is ongoing and is intended to serve as a confirmatory study for the initial indication and has potential to expand the indication regardless of KRAS mutation status.
• The company discontinued the RAMP 204 trial to prioritize the RAMP 203 trial, which is evaluating the combination of avutometinib and sotorasib, with a triplet combination also being evaluated.
• GenFleet began dosing patients in a Phase 1/2 trial in China evaluating VS-7375/GFH375, an oral KRAS G12D inhibitor, in July 2024, and Verastem anticipates filing a U.S. IND application by Q1 2025.

Sentiment

Score: 7

Explanation: The document is generally positive due to the NDA submission and promising clinical data, but there are also risks and uncertainties related to regulatory approvals and future financing.

Positives

• The company successfully completed the NDA submission for avutometinib and defactinib in recurrent KRAS mutant LGSOC.
• The company is seeking accelerated approval and priority review, which could expedite the approval process.
• The RAMP 201 trial data showed promising response rates and tumor reductions.
• The company has a strong cash position of $113.2 million.
• The company is actively preparing for a potential U.S. commercial launch.
• The RAMP 301 trial is progressing and will serve as a confirmatory study.
• The company is advancing its collaboration with GenFleet, with a Phase 1/2 trial underway in China.
• The company has a clear path forward for the KRAS wild-type indication, leveraging data from the RAMP 301 trial.

Negatives

• The company reported a net loss of $24.0 million for the third quarter of 2024.
• Operating expenses increased significantly compared to the same period in 2023.
• The company discontinued the RAMP 204 trial, which may impact its lung cancer program.
• The company is still reliant on future financing to fund its operations.
• The company faces risks and uncertainties related to regulatory approvals and commercialization.

Risks

• The company's ability to obtain regulatory approval for its product candidates is uncertain.
• The company may face delays in clinical trials and regulatory submissions.
• The company's product candidates may not be commercially successful.
• The company may not be able to obtain adequate financing in the future.
• The company faces substantial competition in the pharmaceutical industry.
• The company's market opportunities may be smaller than estimated.
• The company's reliance on third-party organizations for research and manufacturing poses risks.
• The company's collaboration agreements may not be successful.

Future Outlook

The company anticipates an FDA decision on the acceptance of its NDA, plans to submit updated RAMP 201 trial data for publication, and expects to prepare a U.S. IND application for VS-7375 by Q1 2025. The company is also preparing for a potential U.S. commercial launch in mid-2025.

Management Comments

• In the third quarter of 2024, we made advancements in our recurrent low-grade serous ovarian cancer program, including sharing updated Phase 2 RAMP 201 data demonstrating robust and durable response rates, tumor reductions across a majority of patients regardless of their KRAS mutation status, and low discontinuation rates due to adverse events.
• We also completed our rolling NDA submission for recurrent KRAS mutant low-grade serous ovarian cancer and strengthened our balance sheet.
• Looking ahead to the fourth quarter of 2024, we anticipate an FDA decision on the acceptance of our NDA, plan to submit our updated RAMP 201 trial data for publication and expect to prepare a U.S. IND application for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor.

Industry Context

This announcement is significant in the context of the pharmaceutical industry's focus on targeted therapies for cancer, particularly in areas with high unmet medical needs such as LGSOC. The company's focus on RAS/MAPK-driven cancers and its collaborations with other companies in the space highlight the industry's push towards personalized medicine and combination therapies.

Comparison to Industry Standards

• The reported ORR of 44% in KRAS mutant LGSOC patients in the RAMP 201 trial is competitive with other targeted therapies in similar patient populations.
• The company's focus on combination therapies, such as avutometinib with defactinib and with KRAS G12C inhibitors, aligns with the industry trend of exploring synergistic drug combinations to improve patient outcomes.
• The company's decision to prioritize the RAMP 203 trial over the RAMP 204 trial reflects a strategic approach to focus on the most promising clinical programs.
• The company's collaboration with GenFleet for the development of a KRAS G12D inhibitor is in line with the industry's efforts to target specific KRAS mutations, which are prevalent in various cancers.
• The company's cash runway through mid-2025 is a positive sign, but it will need to secure additional funding to support its ongoing clinical programs and commercialization efforts.

Stakeholder Impact

• Shareholders: The NDA submission and positive clinical data are likely to be viewed positively by shareholders, but the company's financial position and reliance on future financing may be a concern.
• Employees: The company's progress in clinical development and commercialization may boost employee morale and motivation.
• Patients: The potential approval of avutometinib and defactinib could provide a new treatment option for patients with recurrent LGSOC.
• Customers: The company's commercial preparation activities indicate a focus on bringing its products to market.
• Suppliers: The company's ongoing clinical trials and commercialization efforts may lead to increased demand for supplies and services.
• Creditors: The company's financial position and reliance on future financing may be a concern for creditors.

Next Steps

• The company anticipates an FDA decision on the acceptance of its NDA.
• The company plans to submit updated RAMP 201 trial data for publication.
• The company expects to prepare a U.S. IND application for VS-7375 by Q1 2025.
• The company will continue to enroll patients in the RAMP 301 trial.
• The company will report updated interim data from the RAMP 203 trial by the end of 2024.
• The company will report updated data from the RAMP 205 trial in Q1 2025.
• The company will continue its commercial preparation activities for a potential U.S. launch in mid-2025.

Key Dates

Keywords

avutometinib, defactinib, LGSOC, KRAS mutant, NDA submission, accelerated approval, RAMP 201, RAMP 301, RAMP 203, VS-7375/GFH375, GenFleet, pancreatic cancer, NSCLC, oncology